Prices delayed by at least 15 minutes | Print


MacroGenics (MGNX)

Common Shares
Sell: $15.83|Buy: $16.95|Change: 0.60 (-3.42%)

Open 

$17.48


Previous close 

$17.54


Trade high 

$17.72


Volume 

820,491


Year high 

$21.88


Year low 

$4.29


Dividend yield 

-


Market capitalisation 

$1.06 bn


P/E ratio 

26.51


ISIN 

US5560991094


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 15/04/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
MacroGenics- 3.42
More...

Company profile

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 CTLA-4), Tebotelimab (PD-1 LAG-3), MGD024 (CD123 CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV CD3).

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.